Patterning the distribution of threatened crayfish and their exotic analogues using self-organizing maps

International audienceAbility to demonstrate statistical patterns of distribution by threatened species and by their potential competitors will determine success in forecasting locations at greatest risk, and ability to target management efforts. A self organizing map algorithm (SOM) was used to derive probabilities of presence of native (Austropotamobius pallipes) and exotic (Orconectes limosus, Pacifastacus leniusculus and Procambarus clarkii) crayfish species with respect to physical and landcover variables in a large stream system, using a simple presence-absence data set of species. Crayfish were sampled at 128 sites representing 86 rivers. The probability of occurrence of the native species increased at higher elevations above sea level and lower temperatures; populations appeared to be mostly confined to headwater streams where exotic competitors were unable to with stand the colder conditions. The distribution of exotic species was correlated with anthropogenic factors, such as the degree of urbanization and agricultural land area. Complementary modelling tools, such as GIS and SOMs, can help to maximize the information extracted from available data in the context of biological conservation

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

International audienceRationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended